Clin­i­cal tri­al dis­rup­tor Sci­ence 37 in talks with Soft­Bank on a $150M in­vest­ment — Re­code

Just a few months af­ter phar­ma gi­ant No­var­tis part­nered up with Sci­ence 37 on its vir­tu­al ap­proach to clin­i­cal tri­al work, Re­code re­ports that the would-be CRO dis­rup­tor is in talks with Soft­Bank ex­ecs on a $150 mil­lion in­vest­ment.

Soft­Bank, which pro­vid­ed Roivant chief Vivek Ra­maswamy with more than a bil­lion dol­lars to in­vest in biotech, ev­i­dent­ly has been drawn to Sci­ence 37’s promise that it can ef­fi­cient­ly and ef­fec­tive­ly re­cruit pa­tients for clin­i­cal tri­als with­out forc­ing them in­to a tri­al site. Us­ing new telemed­i­cine tech, they say they can ac­cu­mu­late clean datasets to show whether or not new drugs are work­ing — hop­ing to dis­rupt the big play­ers who now dom­i­nate the CRO world.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER